NEULANDLAB Neuland Laboratories Q3 FY26 results (Oct–Dec 2025) and concall
Neuland Labs reported an in-line quarter with 11.4% YoY revenue growth, but profitability was impacted by product mix volatility. Management attributed the lower EBITDA and gross margins to shipment delays of two specific high-margin products, terming the quarter's margin profile an 'aberration'. The company is in a ramp-up phase for new CDMO capacities, leading to temporary high working capital, which is expected to normalize. While cautious on near-term guidance due to the 'lumpy' nature of the business, management reiterated confidence in achieving ~30% EBITDA margins in the long run and hi
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.6%, net profit down 60.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 311 | 398 | 328 | 293 | 514 +65% | 440 +11% |
| EBITDA | 61 | 86 | 51 | 34 | 155 +154% | 77 −10% |
| Net profit | 32 | 101 | 28 | 14 | 96 +200% | 40 −60% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
